12.
Paola Morejón Barragán
@paomorejon
Hydroxychloroquine in patients with #COVIDー19: an open-label RCT
150
NOT increase of negative conversion rate… twitter.com/i/web/status/1…
150
NOT increase of negative conversion rate… twitter.com/i/web/status/1…
Retweet of status by @paomorejon
15 Apr 20
copy & paste +upvote -downvote 🚨Hydroxychloroquine in patients with #COVIDー19: an open-label RCT
👥150
NOT increase of negative conversion rate… https://t.co/ryw0sSB0bm
13.
Paola Morejón Barragán
@paomorejon
Statement
The AHA, the HFSA and the ACC recommend continuation of angiotensin converting enzyme inhibitors (ACE-i)… twitter.com/i/web/status/1…
The AHA, the HFSA and the ACC recommend continuation of angiotensin converting enzyme inhibitors (ACE-i)… twitter.com/i/web/status/1…
17 Mar 20
copy & paste +upvote -downvote 📌Statement
The AHA, the HFSA and the ACC recommend continuation of angiotensin converting enzyme inhibitors (ACE-i)… https://t.co/LtV42htm9G
14.
15.
16.
17.
18.
Paola Morejón Barragán
@paomorejon
EHRA international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device… twitter.com/i/web/status/1…
Retweet of status by @paomorejon
28 Feb 20
copy & paste +upvote -downvote 📌EHRA international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device… https://t.co/JXWfy6E2uf
Paola Morejón Barragán
@paomorejon
13728 ARIC cohort
22y
2,696 (20%) developed incident HF, 729 subsequent VTE events
HF (HFpEF/HFrEF)was associ… twitter.com/i/web/status/1…
22y
2,696 (20%) developed incident HF, 729 subsequent VTE events
HF (HFpEF/HFrEF)was associ… twitter.com/i/web/status/1…
Retweet of status by @ValleAlfonso
13 Jan 20
copy & paste +upvote -downvote 👥13728 ARIC cohort
⏰22y
🎯 2,696 (20%) developed incident HF, 729 subsequent VTE events
💡 HF (HFpEF/HFrEF)was associ… https://t.co/pqu2PKz3GW
Paola Morejón Barragán
@paomorejon
Dapagliflozin & Prevention of Adverse outcomes in DAPA-HF
neprilysinBblockerMRASGLT2i
using together is emi… twitter.com/i/web/status/1…
neprilysinBblockerMRASGLT2i
using together is emi… twitter.com/i/web/status/1…
Retweet of status by @ValleAlfonso
03 Jan 20
copy & paste +upvote -downvote Dapagliflozin & Prevention of Adverse outcomes in DAPA-HF⤵️
↪️neprilysin➕Bblocker➕MRA➕SGLT2i
📍using together is emi… https://t.co/XF0H9kaMRe
Paola Morejón Barragán
@paomorejon
Metformin on myocardial efficiency in insulin-resistant chronic #HeartFailure patients without #diabetes
Addition… twitter.com/i/web/status/1…
Addition… twitter.com/i/web/status/1…
22 Dec 19
copy & paste +upvote -downvote 📌Metformin on myocardial efficiency in insulin-resistant chronic #HeartFailure patients without #diabetes
Addition… https://t.co/Qo3u32J9xa
Paola Morejón Barragán
@paomorejon
At the current price of $73 000 per year, adding canakinumab to standard therapy for secondary prevention of cardi… twitter.com/i/web/status/1…
Retweet of status by @ValleAlfonso
17 Jan 19
copy & paste +upvote -downvote 🗣At the current price of $73 000 per year, adding canakinumab to standard therapy for secondary prevention of cardi… https://t.co/VQApfuPFYJ
19.
20.
Paola Morejón Barragán
@paomorejon
I love to read it.
#HeartFailure #InsuficienciaCardiaca #CardioEd pic.twitter.com/KpKaQwf3GH
#HeartFailure #InsuficienciaCardiaca #CardioEd pic.twitter.com/KpKaQwf3GH
30 Aug 18
copy & paste +upvote -downvote I love to read it. 😍
#HeartFailure #InsuficienciaCardiaca #CardioEd https://t.co/KpKaQwf3GH
Paola Morejón Barragán
@paomorejon
Patients with CAD & LVEF>35%, Sudden/arrhythmic death occurred most often at home without antecedent clinical wo… twitter.com/i/web/status/1…
Retweet of status by @ValleAlfonso
19 Jul 18
copy & paste +upvote -downvote Patients with CAD & LVEF>35%, 1️⃣Sudden/arrhythmic death occurred most often at home without antecedent clinical wo… https://t.co/rb0fUJRsuH
...but wait! There's more!
12.
fakhright
@fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
14 Jan 13
copy & paste +upvote -downvote astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat* 🙈🙈🙊